{"Clinical Trial ID": "NCT01808573", "Intervention": ["INTERVENTION 1:", "Neratinib Plus Capecitabine", "\u2022 Neratinib 240 mg orally, once daily with food, continuously in 21-day cycles, and capecitabine 1500 mg/m^2 daily in 2 uniformly distributed doses, orally with water within 30 minutes of a meal, taken on days 1 to 14 of each 21-day cycle.", "INTERVENTION 2:", "- Lapatinib Plus Capecitabine", "\u00b7 Lapatinib 1250 mg orally, once daily, continuously in 21-day cycles, and capecitabine 2000 mg/m^2 daily in 2 uniformly distributed doses, orally with water within 30 minutes of a meal, taken on days 1 to 14 of each 21-day cycle."], "Eligibility": ["Incorporation criteria:", "At 18 years of age upon signature of informed consent.", "Histologically confirmed MBC, current stage IV.", "A documented HER2 overexpression or tumour immunohistochemistry amplified by the 3+ or 2+ gene, with in situ hybridization (FISH) +.", "A prior treatment with at least two (2) HER2-directed regimens for metastatic breast cancer.", "- Exclusion criteria:", "Has received prior treatment with capecitabine, neratinib, lapatinib or any other tyrosine kinase inhibitor led by HER2.", "Note: There are other inclusion and exclusion criteria. The study centre will determine if you meet all the criteria."], "Results": ["Performance measures:", "Central assessment of progression-free survival", "The time interval between the date of randomization and the first date on which recidivism, progression (by criteria for assessing response in solid tumour criteria (RECIST) v1.1) or death for any cause is documented. For subjects without recidivism, progression or death, it is censored during the last assessment of the valid tumour. The progression is defined using the criteria for assessing response in solid tumour criteria (RECIST v1.1), such as an increase of 20% in the sum of the longest diameter of the target lesions, or a measurable increase in non-target injury, or the appearance of new lesions. Here, the event time was reported as the limited mean survival time. The limited mean survival time was defined as the area under the survival function curve up to 24 months.", "Timeline: From the date of randomization to recurrence, progression or death, estimated up to 38 months. The result is based on cut-off primary analytical data.", "Results 1:", "Title of the arm/group: Neratinib Plus Capecitabine", "Description of the arm/group: neratinib 240 mg orally, once daily with food, continuously in 21-day cycles, and capecitabine 1500 mg/m^2 daily in 2 evenly distributed doses, orally with water within 30 minutes of a meal, taken on days 1 to 14 of each 21-day cycle.", "Total number of participants analysed: 307", "Average (95% confidence interval)", "Unit of measure: month 8.8 (7.8 to 9.8)", "Results 2:", "Title of the arm/group: Lapatinib Plus Capecitabine", "Description of the arm/group: lapatinib 1250 mg orally, once daily, continuously in 21-day cycles, and capecitabine 2000 mg/m^2 daily in 2 uniformly distributed doses, orally with water within 30 minutes of a meal, taken on days 1 to 14 of each 21-day cycle.", "Total number of participants analysed: 314", "Average (95% confidence interval)", "Unit of measure: month 6.6 (5.9 to 7.4)"], "Adverse Events": ["Undesirable Events 1:", "Total: 103/303 (33.99%)", "Anemia 1/303 (0.33%)", "Febrile neutropenia 1/303 (0.33%)", "Neutropenia 1/303 (0.33%)", "- Acute myocardial infarction 0/303 (0.00 %)", "Atrial fibrillation 1/303 (0.33%)", "Cardiac arrest 0/303 (0.00 %)", "- Cardiac tapponade 1/303 (0.33%)", "Cardiomyopathy 1/303 (0.33%)", "Palpitations 2/303 (0.66%)", "1/303 (0.33%)", "Tachycardia 0/303 (0.00 %)", "Adverse Events 2:", "Total: 93/311 (29.90 per cent)", "Anemia 2/311 (0.64%)", "Febrile neutropenia 3/311 (0.96%)", "Neutropenia 0/311 (0.00 %)", "Acute myocardial infarction 1/311 (0.32%)", "Atrial fibrillation 0/311 (0.00 %)", "Cardiac arrest 1/311 (0.32%)", "Cardiac Tapponade 1/311 (0.32%)", "Cardiomyopathy 0/311 (0.00 %)", "- Palpitations 0/311 (0.00 %)", "1/311 (0.32%)", "Tachycardia 1/311 (0.32%)"]}